Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at B. Riley from $16.00 to $8.00. They now have a "buy" rating on the stock.
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.